Decision Resources
New drugs will capture share but generic erosion of Fosamax will stymie market
Published in Pharma Law Weekly, September 26th, 2006
The new Pharmacor report Osteoporosis finds that although several emerging drugs will capture significant patient and market share, the entry of generic alendronate will be a major factor in causing the market to plateau at $7.5 billion in 2015, up from $6.3 billion in 2005. The report also finds that bisphosphonates, including alendronate, will continue to dominate the market to treat osteoporosis in the United States, Japan, France, Germany, Italy, Spain,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2006-09-26)
More Articles from Pharma Law Weekly
- AGA Medical
AGA Medical files suit in Germany alleging patent infringement - Bradley Pharmaceuticals
Bradley Pharmaceuticals announces initiatives to enhance shareholder value - Diomed Holdings
Diomed wins motion on validity and enforceability of EVLT patent, trial on infringement expected - Economic and Social Research Council
Increase in drug development for killer diseases hampered by poverty in developing countries - Emory University, U.S.
Studies from the United States, Belgium and Italy describe new findings in surgery research - EntreMed
Method and formulation patent issued for 2ME2 for cancer therapy - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
